Literature DB >> 28864261

The efficacy of (+)-Naltrexone on alcohol preference and seeking behaviour is dependent on light-cycle.

Jonathan Henry W Jacobsen1, Femke T A Buisman-Pijlman1, Sanam Mustafa2, Kenner C Rice3, Mark R Hutchinson4.   

Abstract

Circadian rhythm affects drug-induced reward behaviour and the innate immune system. Peaks in reward-associated behaviour and immune responses typically occur during the active (dark) phase of rodents. While the role of the immune system, specifically, Toll-like receptor 4 (TLR4, an innate immune receptor) in drug-induced reward is becoming increasingly appreciated, it is unclear whether its effects vary according to light-cycle. Therefore, the aim of this study was to characterise the effects of the phase of the light-cycle and the state of the innate immune system on alcohol reward behaviour and subsequently determine whether the efficacy of targeting the immune component of drug reward depends upon the light-cycle. This study demonstrates that mice exhibit greater alcohol-induced conditioned place preference and alcohol two-bottle choice preference during the dark cycle. This effect overlapped with elevations in reward-, thirst- and immune-related genes. Administration of (+)-Naltrexone, a TLR4 antagonist, reduced immune-related gene mRNA expression and alcohol preference with its effects most pronounced during the dark cycle. However, (+)-Naltrexone, like other TLR4 antagonists exhibited off-target side effects, with a significant reduction in overall saccharin intake - an effect likely attributable to a reduction in tyrosine hydroxylase (Th) mRNA expression levels. Collectively, the study highlights a link between a time-of-day dependent influence of TLR4 on natural and alcohol reward-like behaviour in mice.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alcohol; Circadian; Interferon; TRIF; Time-of-day; Toll-like receptor 4; Tyrosine hydroxylase

Mesh:

Substances:

Year:  2017        PMID: 28864261      PMCID: PMC7387101          DOI: 10.1016/j.bbi.2017.08.021

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  59 in total

1.  Ethanol Consumption in Mice Lacking CD14, TLR2, TLR4, or MyD88.

Authors:  Yuri A Blednov; Mendy Black; Julia Chernis; Adriana Da Costa; Jody Mayfield; R Adron Harris
Journal:  Alcohol Clin Exp Res       Date:  2017-02-01       Impact factor: 3.455

2.  Taste reactivity in high alcohol drinking and low alcohol drinking rats.

Authors:  S W Kiefer; N Badia-Elder; P J Bice
Journal:  Alcohol Clin Exp Res       Date:  1995-04       Impact factor: 3.455

Review 3.  Clock genes × stress × reward interactions in alcohol and substance use disorders.

Authors:  Stéphanie Perreau-Lenz; Rainer Spanagel
Journal:  Alcohol       Date:  2015-04-24       Impact factor: 2.405

4.  Evaluation of TLR4 Inhibitor, T5342126, in Modulation of Ethanol-Drinking Behavior in Alcohol-Dependent Mice.

Authors:  M Bajo; S E Montgomery; L N Cates; T Nadav; A M Delucchi; K Cheng; H Yin; E F Crawford; A J Roberts; M Roberto
Journal:  Alcohol Alcohol       Date:  2016-05-05       Impact factor: 2.826

5.  Binge alcohol drinking is associated with GABAA alpha2-regulated Toll-like receptor 4 (TLR4) expression in the central amygdala.

Authors:  Juan Liu; Andrew R Yang; Timothy Kelly; Adam Puche; Chioma Esoga; Harry L June; Ahmed Elnabawi; Istvan Merchenthaler; Werner Sieghart; Harry L June; Laure Aurelian
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-28       Impact factor: 11.205

6.  Impact of TLR4 on behavioral and cognitive dysfunctions associated with alcohol-induced neuroinflammatory damage.

Authors:  María Pascual; Pablo Baliño; Silvia Alfonso-Loeches; Carlos M G Aragón; Consuelo Guerri
Journal:  Brain Behav Immun       Date:  2011-02-23       Impact factor: 7.217

7.  Inhibition of the casein-kinase-1-ε/δ/ prevents relapse-like alcohol drinking.

Authors:  Stéphanie Perreau-Lenz; Valentina Vengeliene; Hamid R Noori; Emilio V Merlo-Pich; Mauro A Corsi; Corrado Corti; Rainer Spanagel
Journal:  Neuropsychopharmacology       Date:  2012-05-02       Impact factor: 7.853

8.  Diurnal differences in dopamine transporter and tyrosine hydroxylase levels in rat brain: dependence on the suprachiasmatic nucleus.

Authors:  Evan P Sleipness; Barbara A Sorg; Heiko T Jansen
Journal:  Brain Res       Date:  2006-12-06       Impact factor: 3.252

9.  Time-of-day differences in dopamine clearance in the rat medial prefrontal cortex and nucleus accumbens.

Authors:  Evan P Sleipness; Heiko T Jansen; James O Schenk; Barbara A Sorg
Journal:  Synapse       Date:  2008-12       Impact factor: 2.562

10.  Multiplex Immunoassay of Plasma Cytokine Levels in Men with Alcoholism and the Relationship to Psychiatric Assessments.

Authors:  Ann M Manzardo; Albert B Poje; Elizabeth C Penick; Merlin G Butler
Journal:  Int J Mol Sci       Date:  2016-03-29       Impact factor: 5.923

View more
  4 in total

1.  Innate Immune Signaling and Alcohol Use Disorders.

Authors:  Leon G Coleman; Fulton T Crews
Journal:  Handb Exp Pharmacol       Date:  2018

Review 2.  Neuroimmune signaling in alcohol use disorder.

Authors:  Emma K Erickson; Emily K Grantham; Anna S Warden; R A Harris
Journal:  Pharmacol Biochem Behav       Date:  2018-12-24       Impact factor: 3.533

3.  Common genetic substrates of alcohol and substance use disorder severity revealed by pleiotropy detection against GWAS catalog in two populations.

Authors:  Qian Peng; Kirk C Wilhelmsen; Cindy L Ehlers
Journal:  Addict Biol       Date:  2020-02-06       Impact factor: 4.280

Review 4.  Immune treatments for alcohol use disorder: A translational framework.

Authors:  Lindsay R Meredith; Elizabeth M Burnette; Erica N Grodin; Michael R Irwin; Lara A Ray
Journal:  Brain Behav Immun       Date:  2021-07-31       Impact factor: 19.227

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.